-
Intec's innovative flu treatment Xofluza (baloxavir marboxil) reaches major end in Phase 3 clinical trial
Time of Update: 2020-06-09
Today, Roche's Genetech company, (http:// , announced that its innovative flu treatment, Baloxavir marboxil, had reached its main point in the global phase 3 clinical trial (http:// called MINI
-
[quick news] on July 3, 2018, baloxavir marboxil, a genetically engineered influenza drug, won the FDA's priority review qualification
Time of Update: 2018-07-03
Baloxavir marboxil, a genetically engineered drug for influenza, has won the FDA's priority evaluation qualification Pharmatimes recently reported that the US FDA will give priority to the evaluation
-
A new generation of anti-flu drugs - Baloxavir marboxil.
Time of Update: 2020-07-21
Text The hydrogen peroxide influenza is an acute respiratory infectious disease caused by influenza virus, mainly spread through contact and air droplets, and is high in winter and summer April 20
-
Gene Tektronix's new heavy flu drug Baloxavir marboxil's Phase 3 study CAPSTONE-2 reaches its main destination
Time of Update: 2020-06-11
today, Genentech, a member of the Roche Group, announced that the , a new drug to assess the efficacy of a new drug heavy influenza, reached its main destination in the phase 3 study CAPSTONE-2, wh
-
FDA approves Genetech's new anti-flu drug, Baloxavir marboxil, for extended indications
Time of Update: 2020-06-07
Today, Roche's Gene (http:// announced that it had approved an extended indication of its new anti-flu drug (http:// , http:// the FDA ( http:// Xofluza will be used to treat people 12 years